ArticleJournal of diabetes research2025
Identification and Verification of Biomarkers Related to Polyamine Metabolism in Diabetic Nephropathy.
Article in Journal of diabetes research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification and Verification of Biomarkers Related to Polyamine Metabolism in Diabetic Nephropathy.Journal of diabetes research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Kidney damage in chronic kidney disease patients is affected by the degradation products of polyamines. However, the effect of polyamine metabolism-related genes (PM-RGs) in diabetic nephropathy (DN) is not clear. The objective of this study is to elucidate the potential correlation between PM-RGs and DN. Methods: DN-related datasets and 59 PM-RGs were obtained from the public database. Then, Differentially Expressed Gene 1 (DEG 1) related to DN in GSE142153 and DEG 2 related to PM-RGs were crossed to obtain intersection genes. The gene with the same expression trend in DEG 3 obtained in GSE185011 and DEG 1 was overlapped with the intersection gene to obtain the candidate genes. Thereafter, two machine learning algorithms and ROC curves were adopted to select biomarkers. Moreover, enrichment analysis, immune infiltration analysis, and drug prediction were implemented to further study the biomarkers. Finally, the expressions of biomarkers were analyzed in clinical samples assessed by RT-qPCR and IHC. Results: KAZALD1, GLCE, and RPRD1B were identified as biomarkers for DN, with their area under the curve values being greater than 0.8. They were involved in multiple biological pathways, such as valine, leucine, and isoleucine degradation, cytokine-cytokine receptor interaction, and peroxisome. Furthermore, immune cells were found to correlate with biomarkers. For instance, the expression of KAZALD1 and RPRD1B showed positive correlations with naive CD8 T cells and M1 macrophages among other immune cells while exhibiting negative correlations with CD8 T cells, B cells, T helper cells, and others. Additionally, based on three biomarkers, 11 drugs (benzopyrene, Bisphenol A, ethinyl estradiol, etc.) were predicted. KAZALD1 and RPRD1B were notably highly expressed in clinical DN samples in RT-qPCR and IHC. Conclusion: The research pinpointed KAZALD1, GLCE, and RPRD1B as biomarkers for DN, offering a novel target reference for diagnosing and treating DN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.